Investor ideas2d
Breaking Medical Technology News: Aethlon (NASDAQ: AEMD) Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and ...
Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that, on September 9, 2024, ...
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...
ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For Malignant Pleural Mesothelioma In Adults
Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy ...
Daily3d
Immunotherapy after surgery may improve survival in people with high-risk bladder cancer: NEJM
Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time ...
Sierra Sun Times4d
NIH Reports Immunotherapy After Surgery Helps People with High-Risk Bladder Cancer Live Cancer-Free Longer
NIH clinical trial results expand treatment options for this disease.
Business Insider4d
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
Merus has confirmed through feedback with the U.S. Food and Drug Administration (FDA) that petosemtamab 1500 mg every two weeks is appropriate for further development in HNSCC as monotherapy, and in ...